中药鹿血晶治疗乳腺浸润导管癌患者化疗后白细胞减少症的临床观察
|
摘要
目的应用中药鹿血晶治疗乳腺浸润性导管癌化疗患者白细胞减少症,观察其临床疗效和对患者生活质量的影响。方法选择辽宁省肿瘤医院2016年1月—2017年12月,120例有明确病理诊断乳腺浸润性导管癌初治患者,将其随机分成研究组和对照组,每组60例。研究组采用TEC(T:多西他赛E:表柔比星C:环磷酰胺)方案化疗,联合鹿血晶治疗;对照组只采用TEC方案化疗,不服用鹿血晶,观察两组白细胞水平的变化、生活质量评分及不良反应。结果一个化疗周期后(用药21天),化疗前及化疗后7天两组白细胞水平差异均无统计学意义(P>0.05),但化疗后14天研究组白细胞水平与对照组比较,差异有统计学意义(P<0.05),对照组患者白细胞计数有所下降。结论中药鹿血晶可升高乳腺浸润导管癌化疗后患者白细胞计数且安全没有不良反应。
Objective Observe and analyze the clinical effect of Luxuejing on leukopenia in breast invasive ductal cancer patients undergoing chemotherapy and its effect on quality of life.Methods From January 2016 to December 2017,120 patients with invasive ductal carcinoma of breast diagnosed by pathology were randomly divided into study group and control group,60 cases in each group.The study group was treated with TEC(T:Docetaxel E:Epirubicin C:Cyclophosphamide) regimen combined with deer blood crystal therapy,while the control group was treated with TEC regimen only,without deer blood crystal.The changes of leucocyte level,quality of life score and adverse reactions were observed in the two groups.Results There was no significant difference in the leucocyte level between the two groups before and 7 days after chemotherapy(P>0.05) after one chemotherapy cycle(21 days after treatment),but the leucocyte level in the study group was significantly higher than that in the control group 14 days after chemotherapy(P<0.05).Leukocyte count decreased in the control group.Conclusion Luxuejing can increase the white blood cell count of patients with breast invasive ductal cancer after chemotherapy,and it is safe and has no adverse reactions.
Objective Observe and analyze the clinical effect of Luxuejing on leukopenia in breast invasive ductal cancer patients undergoing chemotherapy and its effect on quality of life.Methods From January 2016 to December 2017,120 patients with invasive ductal carcinoma of breast diagnosed by pathology were randomly divided into study group and control group,60 cases in each group.The study group was treated with TEC(T:Docetaxel E:Epirubicin C:Cyclophosphamide) regimen combined with deer blood crystal therapy,while the control group was treated with TEC regimen only,without deer blood crystal.The changes of leucocyte level,quality of life score and adverse reactions were observed in the two groups.Results There was no significant difference in the leucocyte level between the two groups before and 7 days after chemotherapy(P>0.05) after one chemotherapy cycle(21 days after treatment),but the leucocyte level in the study group was significantly higher than that in the control group 14 days after chemotherapy(P<0.05).Leukocyte count decreased in the control group.Conclusion Luxuejing can increase the white blood cell count of patients with breast invasive ductal cancer after chemotherapy,and it is safe and has no adverse reactions.
引文
[1] 宋希朋.乳腺癌术后常规化疗辅以中药治疗对患者远期转移复发率及生活质量的影响[J].现代中西医结合杂志,2016,25(33):3670-3672+3715.
[2] 田传兴,李同霞.中西结合治疗对乳腺癌治疗效果、生活质量及预后的评价研究[J].中华中医药学刊,2016,34(9):2283-2285.
[3] 侯公楷.中医药防治乳腺癌进展[J].辽宁中医药大学学报,2016,18(5):249-253.
[4] 董涵之,彭志强,郝晶,等.中药鹿血晶治疗晚期乳腺癌化疗相关性贫血的临床观察[J].实用癌症杂志,2018,33(8):1355-1357.
[5] 邱阚,刘丽娜,种宝贵,等.参附注射液联合TEC新辅助化疗方案治疗绝经前局部晚期乳腺癌效果观察[J].山东医药,2018,58(26):71-73.
[6] 施敏,刘颖,王美鑑,等.鹿血晶联合白细胞介素-11治疗化疗后血小板减少症的临床观察[J].实用癌症杂志,2017,32(9):1454-1456.
[7] 黎国强.探讨补益气血类中药结合西药治疗乳腺癌术后化疗的骨髓抑制现象的临床疗效[J].中国现代药物应用,2018,12(9):99-100.
[8] 曾春生,徐青云,郭守俊,等.鹿血晶预防非小细胞肺癌患者化疗后白细胞减少症的临床效果[J].中国当代医药,2017,24(23):55-57.
[9] 沈海英,鲍方名,顾珉,等.中药饮片鹿血晶PCR检测方法的建立[J].江西中医药,2015,46(10):67-68+76.
[10] 贾奇.浅谈王建华教授中医治疗乳腺癌经验[J].临床医药文献电子杂志,2018,5(71):68+71.
[11] 汤晓霞,谢曼丽,孙珏,等.中药治疗乳腺癌的处方特征分析及辨证思维探讨[J].中国现代医生,2018,56(18):119-122.
[12] 秦美林.探讨补益气血类中药结合西药治疗乳腺癌术后化疗的骨髓抑制现象的疗效[J].临床医药文献电子杂志,2018,5(47):144.
[13] 黎国强.探讨补益气血类中药结合西药治疗乳腺癌术后化疗的骨髓抑制现象的临床疗效[J].中国现代药物应用,2018,12(9):99-100.
[14] 桂奕文,任建琳,朱为康,等.中药联合化疗治疗三阴性乳腺癌疗效Meta分析[J].辽宁中医杂志,2018,45(6):1139-1141.
[15] 王春统,李建文.中药防治乳腺癌的研究进展[J].中国处方药,2018,16(2):18-20.
[16] 石绍先.乳腺癌的中医治疗进展研究[J].内蒙古中医药,2017,36(12):143-144.
[2] 田传兴,李同霞.中西结合治疗对乳腺癌治疗效果、生活质量及预后的评价研究[J].中华中医药学刊,2016,34(9):2283-2285.
[3] 侯公楷.中医药防治乳腺癌进展[J].辽宁中医药大学学报,2016,18(5):249-253.
[4] 董涵之,彭志强,郝晶,等.中药鹿血晶治疗晚期乳腺癌化疗相关性贫血的临床观察[J].实用癌症杂志,2018,33(8):1355-1357.
[5] 邱阚,刘丽娜,种宝贵,等.参附注射液联合TEC新辅助化疗方案治疗绝经前局部晚期乳腺癌效果观察[J].山东医药,2018,58(26):71-73.
[6] 施敏,刘颖,王美鑑,等.鹿血晶联合白细胞介素-11治疗化疗后血小板减少症的临床观察[J].实用癌症杂志,2017,32(9):1454-1456.
[7] 黎国强.探讨补益气血类中药结合西药治疗乳腺癌术后化疗的骨髓抑制现象的临床疗效[J].中国现代药物应用,2018,12(9):99-100.
[8] 曾春生,徐青云,郭守俊,等.鹿血晶预防非小细胞肺癌患者化疗后白细胞减少症的临床效果[J].中国当代医药,2017,24(23):55-57.
[9] 沈海英,鲍方名,顾珉,等.中药饮片鹿血晶PCR检测方法的建立[J].江西中医药,2015,46(10):67-68+76.
[10] 贾奇.浅谈王建华教授中医治疗乳腺癌经验[J].临床医药文献电子杂志,2018,5(71):68+71.
[11] 汤晓霞,谢曼丽,孙珏,等.中药治疗乳腺癌的处方特征分析及辨证思维探讨[J].中国现代医生,2018,56(18):119-122.
[12] 秦美林.探讨补益气血类中药结合西药治疗乳腺癌术后化疗的骨髓抑制现象的疗效[J].临床医药文献电子杂志,2018,5(47):144.
[13] 黎国强.探讨补益气血类中药结合西药治疗乳腺癌术后化疗的骨髓抑制现象的临床疗效[J].中国现代药物应用,2018,12(9):99-100.
[14] 桂奕文,任建琳,朱为康,等.中药联合化疗治疗三阴性乳腺癌疗效Meta分析[J].辽宁中医杂志,2018,45(6):1139-1141.
[15] 王春统,李建文.中药防治乳腺癌的研究进展[J].中国处方药,2018,16(2):18-20.
[16] 石绍先.乳腺癌的中医治疗进展研究[J].内蒙古中医药,2017,36(12):143-144.